FDA announced the Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use.
FDA announced the Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use.
“Too many people suffer unnecessary injuries from avoidable medication misuse, errors and other problems. The FDA is launching the Safe Use Initiative to develop targeted solutions for reducing these injuries,” said FDA Commissioner Margaret A. Hamburg, MD.
Millions of people are harmed every year from inappropriate medication use. Many injuries occur as a result of incomplete access to information about a drug, a patient or the patient’s condition.
Other preventable sources of harm include unintentional misuse of medications, medication abuse, and attempts at self-harm. Unintended exposure to prescription medications such as opioid drugs can cause harm, even death, in a single dose, if taken by someone other than the patient who was prescribed the medication.“This initiative by the FDA to reduce preventable harm from medication use is very important,” said Formulary editorial advisory board member Robert A. Quercia, MS, RPh, clinical pharmacy manager, Department of Pharmacy Services, Hartford Hospital, Hartford, CT.
“Medication safety is a very high priority in healthcare systems today,” Quercia said. “At Hartford, we have a special committee just devoted to medication safety.”
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More